Michael R Marco1, Lihong Zhou1, Sujata Patil2, Jorge E Marcet3, Madhulika G Varma4, Samuel Oommen5, Peter A Cataldo6, Steven R Hunt7, Anjali Kumar8, Daniel O Herzig9, Alessandro Fichera10, Blase N Polite11, Neil H Hyman12, Charles A Ternent13, Michael J Stamos14, Alessio Pigazzi14, David Dietz15, Yuliya Yakunina1, Raphael Pelossof1, Julio Garcia-Aguilar1. 1. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. 2. Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York. 3. Department of Surgery, University of South Florida, Tampa, Florida. 4. Department of Surgery, University of California, San Francisco, San Francisco, California. 5. Department of Surgery, John Muir Health, Concord, California. 6. Department of Surgery, University of Vermont, Burlington, Vermont. 7. Department of Surgery, Washington University, St. Louis, Missouri. 8. Department of Surgery, Washington State University, Spokane, Washington. 9. Department of Surgery, Oregon Health & Science University, Portland, Oregon. 10. Department of Surgery, University of North Carolina, Chapel Hill, North Carolina. 11. Department of Medicine, University of Chicago, Chicago, Illinois. 12. Department of Surgery, University of Chicago, Chicago, Illinois. 13. Department of Surgery, Creighton University Medical Center, University of Nebraska College of Medicine, Omaha, Nebraska. 14. Department of Surgery, University of California, Irvine, Irvine, California. 15. Department of Surgery, University Hospitals Cleveland Medical Center, Cleveland, Ohio.
Abstract
BACKGROUND: Adding modified FOLFOX6 (folinic acid, fluorouracil, and oxaliplatin) after chemoradiotherapy and lengthening the chemoradiotherapy-to-surgery interval is associated with an increase in the proportion of rectal cancer patients with a pathological complete response. OBJECTIVE: The purpose of this study was to analyze disease-free and overall survival. DESIGN: This was a nonrandomized phase II trial. SETTINGS: The study was conducted at multiple institutions. PATIENTS: Four sequential study groups with stage II or III rectal cancer were included. INTERVENTION: All of the patients received 50 Gy of radiation with concurrent continuous infusion of fluorouracil for 5 weeks. Patients in each group received 0, 2, 4, or 6 cycles of modified FOLFOX6 after chemoradiation and before total mesorectal excision. Patients were recommended to receive adjuvant chemotherapy after surgery to complete a total of 8 cycles of modified FOLFOX6. MAIN OUTCOME MEASURES: The trial was powered to detect differences in pathological complete response, which was reported previously. Disease-free and overall survival are the main outcomes for the current study. RESULTS:Of 259 patients, 211 had a complete follow-up. Median follow-up was 59 months (range, 9-125 mo). The mean number of total chemotherapy cycles differed among the 4 groups (p = 0.002), because one third of patients in the group assigned to no preoperative FOLFOX did not receive any adjuvant chemotherapy. Disease-free survival was significantly associated with study group, ypTNM stage, and pathological complete response (p = 0.004, <0.001, and 0.001). A secondary analysis including only patients who received ≥1 cycle of FOLFOX still showed differences in survival between study groups (p = 0.03). LIMITATIONS: The trial was not randomized and was not powered to show differences in survival. Survival data were not available for 19% of the patients. CONCLUSIONS: Adding modified FOLFOX6 after chemoradiotherapy and before total mesorectal excision increases compliance with systemic chemotherapy and disease-free survival in patients with locally advanced rectal cancer. Neoadjuvant consolidation chemotherapy may have benefits beyond increasing pathological complete response rates. See Video Abstract at http://links.lww.com/DCR/A739.
RCT Entities:
BACKGROUND: Adding modified FOLFOX6 (folinic acid, fluorouracil, and oxaliplatin) after chemoradiotherapy and lengthening the chemoradiotherapy-to-surgery interval is associated with an increase in the proportion of rectal cancerpatients with a pathological complete response. OBJECTIVE: The purpose of this study was to analyze disease-free and overall survival. DESIGN: This was a nonrandomized phase II trial. SETTINGS: The study was conducted at multiple institutions. PATIENTS: Four sequential study groups with stage II or III rectal cancer were included. INTERVENTION: All of the patients received 50 Gy of radiation with concurrent continuous infusion of fluorouracil for 5 weeks. Patients in each group received 0, 2, 4, or 6 cycles of modified FOLFOX6 after chemoradiation and before total mesorectal excision. Patients were recommended to receive adjuvant chemotherapy after surgery to complete a total of 8 cycles of modified FOLFOX6. MAIN OUTCOME MEASURES: The trial was powered to detect differences in pathological complete response, which was reported previously. Disease-free and overall survival are the main outcomes for the current study. RESULTS: Of 259 patients, 211 had a complete follow-up. Median follow-up was 59 months (range, 9-125 mo). The mean number of total chemotherapy cycles differed among the 4 groups (p = 0.002), because one third of patients in the group assigned to no preoperative FOLFOX did not receive any adjuvant chemotherapy. Disease-free survival was significantly associated with study group, ypTNM stage, and pathological complete response (p = 0.004, <0.001, and 0.001). A secondary analysis including only patients who received ≥1 cycle of FOLFOX still showed differences in survival between study groups (p = 0.03). LIMITATIONS: The trial was not randomized and was not powered to show differences in survival. Survival data were not available for 19% of the patients. CONCLUSIONS: Adding modified FOLFOX6 after chemoradiotherapy and before total mesorectal excision increases compliance with systemic chemotherapy and disease-free survival in patients with locally advanced rectal cancer. Neoadjuvant consolidation chemotherapy may have benefits beyond increasing pathological complete response rates. See Video Abstract at http://links.lww.com/DCR/A739.
Authors: Julio Garcia-Aguilar; Oliver S Chow; David D Smith; Jorge E Marcet; Peter A Cataldo; Madhulika G Varma; Anjali S Kumar; Samuel Oommen; Theodore Coutsoftides; Steven R Hunt; Michael J Stamos; Charles A Ternent; Daniel O Herzig; Alessandro Fichera; Blase N Polite; David W Dietz; Sujata Patil; Karin Avila Journal: Lancet Oncol Date: 2015-07-14 Impact factor: 41.316
Authors: Mark S Roh; Linda H Colangelo; Michael J O'Connell; Greg Yothers; Melvin Deutsch; Carmen J Allegra; Morton S Kahlenberg; Luis Baez-Diaz; Carol S Ursiny; Nicholas J Petrelli; Norman Wolmark Journal: J Clin Oncol Date: 2009-09-21 Impact factor: 44.544
Authors: K Bujko; L Wyrwicz; A Rutkowski; M Malinowska; L Pietrzak; J Kryński; W Michalski; J Olędzki; J Kuśnierz; L Zając; M Bednarczyk; M Szczepkowski; W Tarnowski; E Kosakowska; J Zwoliński; M Winiarek; K Wiśniowska; M Partycki; K Bęczkowska; W Polkowski; R Styliński; R Wierzbicki; P Bury; M Jankiewicz; K Paprota; M Lewicka; B Ciseł; M Skórzewska; J Mielko; M Bębenek; A Maciejczyk; B Kapturkiewicz; A Dybko; Ł Hajac; A Wojnar; T Leśniak; J Zygulska; D Jantner; E Chudyba; W Zegarski; M Las-Jankowska; M Jankowski; L Kołodziejski; A Radkowski; U Żelazowska-Omiotek; B Czeremszyńska; L Kępka; J Kolb-Sielecki; Z Toczko; Z Fedorowicz; A Dziki; A Danek; G Nawrocki; R Sopyło; W Markiewicz; P Kędzierawski; J Wydmański Journal: Ann Oncol Date: 2016-02-15 Impact factor: 32.976
Authors: J Joshua Smith; Oliver S Chow; Marc J Gollub; Garrett M Nash; Larissa K Temple; Martin R Weiser; José G Guillem; Philip B Paty; Karin Avila; Julio Garcia-Aguilar Journal: BMC Cancer Date: 2015-10-23 Impact factor: 4.430
Authors: Ebunoluwa E Otegbeye; Jonathan B Mitchem; Haeseong Park; Aadel A Chaudhuri; Hyun Kim; Matthew G Mutch; Matthew A Ciorba Journal: Transl Res Date: 2020-12-08 Impact factor: 7.012
Authors: Ewa Kosakowska; Lucyna Pietrzak; Wojciech Michalski; Lucyna Kepka; Wojciech Polkowski; Malgorzata Jankiewicz; Bogumila Cisel; Jacek Krynski; Jacek Zwolinski; Lucjan Wyrwicz; Andrzej Rutkowski; Roman Stylinski; Grzegorz Nawrocki; Rafal Sopylo; Marek Szczepkowski; Wieslaw Tarnowski; Krzysztof Bujko Journal: Rep Pract Oncol Radiother Date: 2020-08-16
Authors: Agastya Patel; Piotr Spychalski; Giulia Corrao; Barbara A Jereczek-Fossa; Robert Glynne-Jones; Julio Garcia-Aguilar; Jarek Kobiela Journal: Acta Oncol Date: 2021-07-24 Impact factor: 4.311
Authors: Philip S Bauer; William C Chapman; Chady Atallah; Bilal A Makhdoom; Aneel Damle; Radhika K Smith; Paul E Wise; Sean C Glasgow; Matthew L Silviera; Steven R Hunt; Matthew G Mutch Journal: Ann Surg Date: 2022-02-01 Impact factor: 13.787